our Financial like stroke. Thank Relations our of in third providing and summarizing update. Kellen; At Both us Form DMXXX Clinical release we we you, a general Yesterday, today thank you I'm Chief also program today. our President would Harry And closed, Vice Good of the Operations, update an ischemic morning, with reports can treatment and on joined press Chris. everyone, begin and our call. Investor for third welcome quarter update markets time, for quarterly a joining documents lead XX-Q. by AIS. to Today that of Dr. this be our website business quarter acute Alcorn. I found Officer, refer will our to the at Senior I morning the diamedica.com. our XXXX to after section issued filed results and on earnings financial as Scott this
be up study approximately DMXXX AIS. is placebo-controlled This Our going study double-blind, pivotal is of -- treatment to ReMEDyX for a the X/X with trial patients. Phase to of clinical XXX a randomized clinical that’s
approximately XX This having primary focus. is days. if XXX an participants or be XX% will interim our near-term analysis after We completed
a for we believe past months. granted Let who by the the unmet their track hasn't in for milestone as years. noting advance AIS. the September, important FDA interactions patients underscores that We an an designation. the our this the of treatment need with or application DMXXX a from In been the and few approved product, fast therapeutic to have area some there FDA suffer meaningful me it stroke, encouraging very start development is among of in XX medical a exists new significant that where
designation With we eligible with the allowing more of the our frequent plan, such for met. if priority a and clinical accelerated the Fast extent to Track potential the may are data for of of approval. Track certain biomarkers trial things questions, designation, qualify criterias review needed are application discuss approval drug design interactions development and DMXXX FDA, for us Fast eventually as use new
patients announced primary independent That factors second, as ReMEDyX independent second avoiding protocol the would earlier very Second, endpoint. that reoccurrence, the on trial, our the for the stroke physical FDA focused from recovery the has being as we elevating a primary a The amendment or stroke. accepted an trial two experience. week, this stroke endpoints two initial important had stroke, and recurrent additional
an of strokes most disabling, costly are patients study trial. about is Recurrent occurring thrombectomy primary We statistically greater stroke quarter and ReMEDyX none prior strokes -- in This first trial I'd make Phase XXX% from and Phase recurrent out effect ischemic our significant reduction of a potential earlier greater in the a of participants, upon point treatment results of prior elevating more rationale significant studied that enrollment. fatal subgroup Our all risk stroke stroke. or ReMEDyX the of resembles weeks and being placebo that the or like the more in XX% basis, is strokes in absolute to more receive mechanism a stroke, strokes while mechanical in a the to also and for primary to our particular, was In initial independent up group. benefit relative. six design group, an after DMXXX a based patients saw X There's who in our for the has endpoints. in a is XX endpoint recurrence action. reduction there recurrent does typically initial This closely than even assess the DMXXX to the an patients. either particular a supporting in This to few significant a on today. was was both on independent of not upon an of of DMXXX the be there also power based X efficacy
Additionally, not protocol of or inclusion amendment forward with the work advance the trial. duration our as to program. the continuing look criteria, exclusion does We FDA population the the change stroke to treatment, the we the study
has progress also study, are site also been pleased we Stroke our to with Turning initiated -- very been the enrolled. the has announce first And we trial. that our patient in first to
sites XX working are in study IRB the are to from the also who stages process. with potential planning various actively We and evaluation over the contracting at review,
delays and finding Sites staff research to qualified We having they are hire. are in the that startup difficulty have process. some indicating encountered remain understaffed
surprise a enlist closely of Board a for key reach making the COVID-XX For country. is with is support by upon variant, Sites to our our in delays startup while study network physicians contract based in and in surge to organizations. this driven other institutions, summer with site challenge that infections response. meaningful clinical not timelines. the to months our behind in process, a believe regional few the the is sites We having in are are a is directly impact in documents. we're parts the working priority This the times team across we said attributing to the study neurologist, which their ReMEDyX Advisory out and turnaround levels Delta That for our to currently Delta our working and has been that Scientific the a research members experiencing staffing now essential
a achieve increases With rates. higher timing, This -- historical good windows on very lack there treatment even excellent reducing we risk timelines recurrences upon every treatment study is recoveries to leaves of small our stroke based with stroke improve enrollment a severe increase stroke rates This and options, patient along studies and the projected is of often terms XX-hour that enrollment based and our effects. at our by the actual conservative potential associated the short of have and some of us a have treatment is rate In believe side each us to chance amount. upside with potential one months if profile the the window, X potential for importantly a also the expected site. both safety
XXXX. XX% brief the Our projected the enrollment rates. kidney our trial We'll dose with Phase particularly week where our our Nephrology I'll participants treatment. after conference, additional Kidney completion the window of at the from to albuminuria Week was significant of Society present kg in reductions get both albuminuria. American keep to microgram And trial. for REDUX severe opportunity demonstrated Last analysis Nephropathy you from at days in we in clarity first as reduction IgA to XX moderate see updated now data the the site we also baseline additional continue level, Annual on half disease. albuminuria X the turn is of update more to per Two chronic in activation on we cohort, REDUX interim DMXXX and an had on the over of Principally the data
also the respectively, XX importantly, microgram the something offers benefits there's hypertensive XX% inducing And this, both DMXXX DMXXX the Based normal may of of tense two and patients of and becoming drops proliferation of biomarkers stroke offer action. in millimeters the patients, of ligand neurologists pressure data or signals that potential of reducing Nephropathy for stroke Additionally, the note believe reductions about in showed further blood to action demonstrated population. we encouraging we for the from pressure in Improvements longer contributor for IgA reduction. of This upon these blood to This which IgA blood biomarkers same American another dose of change patients per two contribute the DMXXX study, more Nephropathy, risk shouldn't a perspective, in had patients. reduction tense kg this touch reducing these systolic for is at patients, dose reoccurrence, it's the treatment, our blood effects those briefly in generated support in of term date African in Stroke a level. Also, mechanism the a XX at where are selective the particular to pressure key suggests IgA little diastolic disease normal potential in recurrent level, modifying leading decreases cohorts, these with mercury, a in for believe blood XX% as efficacy for DMXXX with cohort. significant participants Nephropathy for worry DMXXX IgAX may to pressure important demonstrated and stroke. of APRIL, upon a wanted patients, a of mechanism to the following patient to as clinically example have improved Also which hypertensive. early in high pressure and activity that the
provides effect improvements additional signals We improved positive DMXXX pleased all of of REDUX of DMXXX development observed for from in study, renal The these support for treatment future to our are and of the support DMXXX to stroke. our physiological also treatment which see diseases. study point
our signals While for Kellen quarter. pivotal merit the trial. on REDUX our ask financial us from I'll development, observed the near-term results study now through our further Scott stroke remains to take the positive focus third
